106 related articles for article (PubMed ID: 17970092)
1. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Palwai NR; Zang XP; Harrison RG; Pento JT
Anticancer Res; 2007; 27(5A):3435-9. PubMed ID: 17970092
[TBL] [Abstract][Full Text] [Related]
2. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Zang XP; Palwai NR; Lerner MR; Brackett DJ; Pento JT; Harrison RG
Anticancer Res; 2006; 26(3A):1745-51. PubMed ID: 16827102
[TBL] [Abstract][Full Text] [Related]
3. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Peron K; Jones TN; Gauthier SA; Nguyen TN; Zang XP; Barriere M; Prévéraud D; Soliman CE; Harrison RG; Pento JT
Cancer Chemother Pharmacol; 2003 Oct; 52(4):270-6. PubMed ID: 12827296
[TBL] [Abstract][Full Text] [Related]
4. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.
Palwai NR; Zang XP; Harrison RG; Benbrook D; Pento JT
Pharmacology; 2009; 84(5):271-5. PubMed ID: 19797936
[TBL] [Abstract][Full Text] [Related]
5. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
[TBL] [Abstract][Full Text] [Related]
6. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
7. Anticancer efficacy of methioninase in vivo.
Tan Y; Xu M; Guo H; Sun X; Kubota T; Hoffman RM
Anticancer Res; 1996; 16(6C):3931-6. PubMed ID: 9042315
[TBL] [Abstract][Full Text] [Related]
8. Gene cloning and characterization of Pseudomonas putida L-methionine-alpha-deamino-gamma-mercaptomethane-lyase.
Hori H; Takabayashi K; Orvis L; Carson DA; Nobori T
Cancer Res; 1996 May; 56(9):2116-22. PubMed ID: 8616859
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
10. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro.
Tan Y; Xu M; Hoffman RM
Anticancer Res; 2010 Mar; 30(3):793-8. PubMed ID: 20392998
[TBL] [Abstract][Full Text] [Related]
11. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase.
El-Sayed AS; Shouman SA; Nassrat HM
Enzyme Microb Technol; 2012 Sep; 51(4):200-10. PubMed ID: 22883554
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
14. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells.
Huang YW; Wang LS; Dowd MK; Wan PJ; Lin YC
Anticancer Res; 2009 Jun; 29(6):2179-88. PubMed ID: 19528479
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
16. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.
Massoner P; Colleselli D; Matscheski A; Pircher H; Geley S; Jansen Dürr P; Klocker H
Endocr Relat Cancer; 2009 Sep; 16(3):795-808. PubMed ID: 19509068
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
18. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides.
Makovitzki A; Fink A; Shai Y
Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852
[TBL] [Abstract][Full Text] [Related]
19. Depletion of serum methionine by methioninase in mice.
Lishko VK; Lishko OV; Hoffman RM
Anticancer Res; 1993; 13(5A):1465-8. PubMed ID: 8239522
[TBL] [Abstract][Full Text] [Related]
20. Microbial L-methioninase: production, molecular characterization, and therapeutic applications.
El-Sayed AS
Appl Microbiol Biotechnol; 2010 Mar; 86(2):445-67. PubMed ID: 20146062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
